MESIANO, GIULIA
 Distribuzione geografica
Continente #
NA - Nord America 542
EU - Europa 188
AS - Asia 108
SA - Sud America 2
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 842
Nazione #
US - Stati Uniti d'America 537
IT - Italia 63
CN - Cina 58
IE - Irlanda 35
SE - Svezia 30
VN - Vietnam 18
SG - Singapore 17
FR - Francia 14
FI - Finlandia 11
UA - Ucraina 10
DE - Germania 7
BE - Belgio 6
KR - Corea 6
CA - Canada 5
HK - Hong Kong 5
NO - Norvegia 4
GB - Regno Unito 3
IN - India 2
JP - Giappone 2
PL - Polonia 2
AR - Argentina 1
BR - Brasile 1
BY - Bielorussia 1
EU - Europa 1
LV - Lettonia 1
MA - Marocco 1
NL - Olanda 1
Totale 842
Città #
Chandler 74
Houston 59
Fairfield 40
Beijing 37
Dublin 35
Ann Arbor 28
Ashburn 26
Cambridge 22
Nyköping 17
Torino 17
Woodbridge 17
Jacksonville 16
Seattle 16
Singapore 11
Turin 11
Wilmington 11
Princeton 10
Fremont 9
Medford 9
Dearborn 8
Villeurbanne 8
Brussels 6
Detroit 6
Dong Ket 6
Munich 5
San Diego 5
Shanghai 4
Boardman 3
Boston 3
Hanoi 3
Hong Kong 3
Kunming 3
Ottawa 3
San Mateo 3
Stavanger 3
Washington 3
Cuneo 2
Fort Worth 2
Hangzhou 2
Nanjing 2
New York 2
Pisa 2
Toronto 2
Upper Marlboro 2
Warsaw 2
Alessandria 1
Bengaluru 1
Brescia 1
Cagliari 1
Camporosso 1
Central District 1
Chengdu 1
Des Moines 1
Düsseldorf 1
Englewood 1
Fuzhou 1
Gorizia 1
Guangzhou 1
Guiyang 1
Hebei 1
Hefei 1
Helsinki 1
Mestre 1
Milan 1
Minatomirai 1
Moncalieri 1
Mountain View 1
Norwalk 1
Oslo 1
Palermo 1
Recife 1
Riverton 1
Rome 1
Rouen 1
Saint-sulpice-et-cameyrac 1
Salé 1
San Nicolas 1
Seoul 1
Settimo Torinese 1
Sìnnai 1
Tamworth 1
Tappahannock 1
Tokyo 1
Wuhan 1
Xian 1
Totale 598
Nome #
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. 147
Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity 127
Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients 107
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes 98
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer 82
Adoptive immunotherapy against sarcomas. 78
Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. 76
Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation 68
Epha2 expression in bone sarcomas: Bioinformatic analyses and preclinical characterization in patient-derived models of osteosarcoma, ewing’s sarcoma and chondrosarcoma 55
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST 30
Correction to: Cytokines induced killer cells produced in good manufacturing practices conditions: Identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity (Journal of Translational Medicine (2018) 16 (237) DOI: 10.1186/s12967-018-1613-5) 2
Totale 870
Categoria #
all - tutte 3.127
article - articoli 0
book - libri 0
conference - conferenze 271
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.398


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020121 1 1 0 3 4 52 7 8 6 14 15 10
2020/2021167 10 56 11 7 10 13 4 8 7 8 11 22
2021/2022153 9 2 6 9 9 4 13 11 5 10 51 24
2022/2023224 17 22 2 25 9 58 17 14 38 12 10 0
2023/202499 12 23 7 3 4 15 3 10 0 1 11 10
2024/20251 1 0 0 0 0 0 0 0 0 0 0 0
Totale 870